Matches in Wikidata for { <http://www.wikidata.org/entity/Q90004818> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q90004818 description "article scientifique publié en 2020" @default.
- Q90004818 description "artículu científicu espublizáu en febreru de 2020" @default.
- Q90004818 description "im Februar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90004818 description "scientific article published on 14 February 2020" @default.
- Q90004818 description "wetenschappelijk artikel" @default.
- Q90004818 description "наукова стаття, опублікована 14 лютого 2020" @default.
- Q90004818 name "Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine)" @default.
- Q90004818 name "Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine)" @default.
- Q90004818 type Item @default.
- Q90004818 label "Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine)" @default.
- Q90004818 label "Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine)" @default.
- Q90004818 prefLabel "Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine)" @default.
- Q90004818 prefLabel "Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine)" @default.
- Q90004818 P1433 Q90004818-74318642-6F2C-4B26-AB8B-F1172E99F897 @default.
- Q90004818 P1476 Q90004818-AE7EA9E9-544E-413F-92B1-98DC8B4FFE85 @default.
- Q90004818 P2093 Q90004818-1F41C9F9-1FBC-42C6-8466-D2766EA62DFA @default.
- Q90004818 P2093 Q90004818-2849A7D6-C510-41E9-B996-C86C162F00EC @default.
- Q90004818 P2093 Q90004818-40E17DC7-1472-4893-A6AB-7118CEB80321 @default.
- Q90004818 P2093 Q90004818-6090C952-CCA3-4AC4-877A-6F0520CA59F8 @default.
- Q90004818 P2093 Q90004818-6EC3E392-A0A1-4724-9779-80B910897AEB @default.
- Q90004818 P2093 Q90004818-B8C179E0-EEB0-4A85-B2A4-42509A5C6BB6 @default.
- Q90004818 P304 Q90004818-4EE00FBD-E539-4425-B08A-E7BAC10CE598 @default.
- Q90004818 P31 Q90004818-7E6D0349-F93F-4A1E-B9D9-B4EE4364FC62 @default.
- Q90004818 P356 Q90004818-B4E0806A-0013-4C07-8AA8-41AE40425545 @default.
- Q90004818 P577 Q90004818-DE748726-60D4-4BDA-B65B-2CFE28DA1206 @default.
- Q90004818 P698 Q90004818-34D18690-EB20-49E8-BF3B-E025748028AF @default.
- Q90004818 P921 Q90004818-884E06CA-7B64-484D-A551-6511BDFF7C86 @default.
- Q90004818 P356 J.LEUKRES.2020.106318 @default.
- Q90004818 P698 32127177 @default.
- Q90004818 P1433 Q15716445 @default.
- Q90004818 P1476 "Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine)" @default.
- Q90004818 P2093 "Asad Bashey" @default.
- Q90004818 P2093 "H Kent Holland" @default.
- Q90004818 P2093 "Lawrence E Morris" @default.
- Q90004818 P2093 "Melhem M Solh" @default.
- Q90004818 P2093 "Scott R Solomon" @default.
- Q90004818 P2093 "Xu Zhang" @default.
- Q90004818 P304 "106318" @default.
- Q90004818 P31 Q13442814 @default.
- Q90004818 P356 "10.1016/J.LEUKRES.2020.106318" @default.
- Q90004818 P577 "2020-02-14T00:00:00Z" @default.
- Q90004818 P698 "32127177" @default.
- Q90004818 P921 Q180983 @default.